FDA approves Livsayis for generalized myasthenia gravis
The FDA has approved Livsayis as the first small interfering RNA treatment for generalized myasthenia gravis with subcutaneous dosing to be administered every 3 months.
Livsayis (cemdisiran, Regeneron Pharmaceuticals) was accepted for priority review by the FDA in July. The treatment has shown rapid and sustained disease control, Tuan Vu, MD, professor of neurology at the University of South Florida Morsani College of Medicine, said in a press release.
“Livsayis delivered rapid, deep disease control, maintained through the end of dosing intervals, and offers a four-times-a-year subcutaneous